A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
R-Pharm
Seagen Inc.
Pfizer
Eli Lilly and Company
AstraZeneca
Pfizer
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
AbbVie
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Parabilis Medicines, Inc.
Seagen Inc.
Summit Therapeutics
Vejle Hospital
Novartis
Ono Pharmaceutical Co., Ltd.
Eastern Cooperative Oncology Group
EMD Serono
SCRI Development Innovations, LLC
Multitude Therapeutics Inc.
Pfizer
Sun Yat-sen University
Akeso
Fudan University
Seagen Inc.
AstraZeneca
Inova Health Care Services
Luye Pharma Group Ltd.
Institut du Cancer de Montpellier - Val d'Aurelle
Memorial Sloan Kettering Cancer Center
Duke University
University of Campania Luigi Vanvitelli
Bold Therapeutics, Inc.
City of Hope Medical Center
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
Gruppo Oncologico del Nord-Ovest
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Allama Iqbal Medical College
GlaxoSmithKline
Sun Yat-sen University
Tyligand Pharmaceuticals (Suzhou) Limited
Charite University, Berlin, Germany
City of Hope Medical Center
University Health Network, Toronto